Impact Health is a mission-driven health policy and strategic consulting firm dedicated to improving health and well-being for all.
OUR SERVICES
Strategic Planning
Integrate mission-aligned policy expertise and political acumen into planning and executing your goals.
Government Contracting
Track record of success supporting states and municipalities in innovating or launching new programs.
Our proprietary method for tracking, aggregating, and analyzing state policy trends.
If you believe that every American deserves to be healthy and well, contact Impact Health Policy Partners to learn how our expertise can help you achieve your goals.
Policy Hub, managed by Impact Health Policy Partners, is the only comprehensive database of Federal health policy developments, cataloged by over 200 healthcare topics and programs. Regulations, reimbursement, grants, ACA implementation, hearing summaries, CRS Reports, pending legislation – you get it all here, with comprehensive, expert analysis.
Agency Issues Proposed Rule Implementing H.R 1 Provider Tax Limits, Revisits Definitions of Enacted and Imposed Taxes
The Centers for Medicare and Medicaid Services (CMS) issued a proposed rule on how the agency expects to implement changes to health-care related (provider taxes) contained in H.R.1. What it is. H.R. 1 established a new indirect hold harmless threshold effective October 1, 2026. For states that have not expanded Medicaid, the new hold harmless threshold requires that the state… (Marceno, July 22, 2026) #Cost-Sharing, #Program Integrity, #Workforce
Committee Advances Legislation Addressing Price Transparency, Insulin affordability, Diabetes Prevention, Biosimilars, Food safety, Prescription Drug Labeling and Compounding, and Workforce
Today, the Senate Health, Education, Labor and Pensions (HELP) Committee convened a markup to consider the following legislation. All bills were favorably advanced to the Senate floor. S. 1414, Expedited Access to Biosimilar Act (manager’s amendment, section-by-section): The bill eliminates the requirement for biosimilar under development to conduct studies assessing immunogenicity, pharmacodynamics, or comparative clinical efficacy, in an effort to… (Slifer, July 22, 2026) #Nutrition, #Prescription Drugs, #Transparency, #Workforce



